Amy Bur­roughs to lead Cleave Ther­a­peu­tics; Cyn­thia Collins clinch­es Ed­i­tas CEO job amid his­toric CRISPR move

→ Af­ter bag­ging $12 mil­lion to ad­vance its lead drug can­di­date CB-5339 — a (VCP)/p97 in­hibitor — through ear­ly clin­i­cal de­vel­op­ment, Cleave Ther­a­peu­tics is beef­ing up its ex­ec­u­tive team. Amy Bur­roughs will be lead­ing the helm as CEO while Scott Har­ris joins as COO. Bur­roughs was an ex­ec­u­tive-in-res­i­dence at 5AM Ven­tures, which led the re­cent fi­nanc­ing, where she al­so served as a strate­gic com­mer­cial ad­vi­sor to port­fo­lio com­pa­ny Cri­net­ics Phar­ma­ceu­ti­cals. Giv­en her ear­ly ex­pe­ri­ence with the team at Genen­tech and back­ground in life sci­ences con­sult­ing, Bur­roughs brings crit­i­cal per­spec­tives on “un­der­stand­ing mar­ket needs, build­ing part­ner­ships and at­tract­ing top-notch tal­ent,” said board chair­man and for­mer Cleave CEO Lau­ra Shawver.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.